Interestingly, high level of SNRPD1 conveys poor prognostic value on ER-HER2- (mostly TNBC) and ER+HER2- (corresponding to luminal A) tumors, but implicates favorable clinical outcome on ER-HER2+ (HER2+ tumors) breast cancers. Here, ERBB2 is linked to breast carcinoma.